RNTX
Rein Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.85 / 10
Netural
Analyst coverage is thin, with a single neutral rating and overall bearish sentiment. Market expectations are pessimistic as the stock fell 8% recently. Nonetheless, fund flow remains strong (7.7/10) with broad inflows across most investor sizes, offsetting medium‑size outflows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionBrookline Capital
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for RNTX?
- RNTX holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.85/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
